Adjuvant platinum-based chemotherapy in non-small cell lung cancer: The role of relative dose-intensity and treatment delay

Burdett, 2015, Adjuvant chemotherapy for resected early-stage non-small cell lung cancer, Cochrane Database Syst Rev Strauss, 2008, Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups, J Clin Oncol, 26, 5043, 10.1200/JCO.2008.16.4855 Cuffe, 2012, A pooled exploratory analysis of the effect of tumor size and KRAS mutations on survival benefit from adjuvant platinum-based chemotherapy in node-negative non-small cell lung cancer, J Thorac Oncol, 7, 963, 10.1097/JTO.0b013e31824fe9e6 Winton, 2005, Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer, N Engl J Med, 352, 2589, 10.1056/NEJMoa043623 Butts, 2010, Randomized phase III trial of vinorelbine plus cisplatin compared with observation in completely resected stage IB and II non-small-cell lung cancer: updated survival analysis of JBR-10, J Clin Oncol, 28, 29, 10.1200/JCO.2009.24.0333 Douillard, 2006, Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial, Lancet Oncol, 7, 719, 10.1016/S1470-2045(06)70804-X Postmus, 2017, Early and locally advanced non-small cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol, 28, iv1, 10.1093/annonc/mdx222 Ramsden, 2015, Adjuvant chemotherapy in resected stage II non-small cell lung cancer: evaluating the impact of dose intensity and time to treatment, Clin Oncol, 27, 394, 10.1016/j.clon.2015.03.001 Salazar, 2017, Association of delayed adjuvant chemotherapy with survival after lung cancer surgery, JAMA Oncol, 3, 610, 10.1001/jamaoncol.2016.5829 Booth, 2013, Time to adjuvant chemotherapy and survival in non-small cell lung cancer: a population-based study, Cancer, 119, 1243, 10.1002/cncr.27823 Wang, 2016, Impact on survival on interval between surgery and adjuvant chemotherapy in completely resected stage IB-IIIA Lung cancer, PLoS ONE, 11, 1, 10.1371/journal.pone.0163809 Pignon, 2008, Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group, J Clin Oncol, 26, 3552, 10.1200/JCO.2007.13.9030 Arriagada, 2004, The International Adjuvant Lung Cancer Trial Collaborative Group: cisplatin-based adjuvant chemotherapy in patients with completely resected nonsmall cell lung cancer, N Engl J Med, 350, 351, 10.1056/NEJMoa031644 Stephens, 2000, The Big Lung Trial (BLT): a major randomised trial to determine the value of cisplatin-based chemotherapy for all patients with non-small cell lung cancer (NSCLC), Lung Cancer, 20, 10.1016/S0169-5002(00)80061-6 Hryniuk, 1990, The calculation of received dose intensity, J Clin Oncol, 8, 1935, 10.1200/JCO.1990.8.12.1935 Havrilesky, 2015, A review of relative dose intensity and survival in patients with metastatic solid tumors, Crit Rev Oncol Hematol, 93, 203, 10.1016/j.critrevonc.2014.10.006 Bonadonna, 1981, Dose-response effect of adjuvant chemotherapy in breast cancer, N Engl J Med, 304, 10, 10.1056/NEJM198101013040103 Brunetto, 2010, Modest reductions in dose intensity and drug-induced neutropenia have no major impact on survival of patients with non-small cell lung cancer treated with platinum-doublet chemotherapy, J Thorac Oncol, 5, 1397, 10.1097/JTO.0b013e3181eba7f9 Luciani, 2009, Dose intensity correlate with survival in elderly patients treated with chemotherapy for advanced non-small cell lung cancer, Lung Cancer, 66, 94, 10.1016/j.lungcan.2008.12.019 Crawford, 2020, Relative dose intensity of first-line chemotherapy and overall survival in patients with advanced non-small-cell lung cancer, Support Care Cancer, 28, 925, 10.1007/s00520-019-04875-1 Goldstraw, 2007, The IASLC Lung Cancer Staging Project: proposals for the Revision of the TNM Stage Groupings in the Forthcoming (Seventh) Edition of the TNM Classification of Malignant Tumours, J Thorac Oncol, 2, 706, 10.1097/JTO.0b013e31812f3c1a Mountain, 1997, Revisions in the international system for staging lung cancer, Chest, 111, 1710, 10.1378/chest.111.6.1710 Dafni, 2011, Landmark analysis at the 25-year landmark point, Circ. Cardiovasc Qual Outcomes, 363, 10.1161/CIRCOUTCOMES.110.957951 Mosteller, 1987, Simplified calculation of body-surface area, N Engl J Med, 317, 1098, 10.1056/NEJM198710223171717 Cortes, 2015, Adjuvant chemotherapy in non-small cell lung cancer: state-of the art, Transl Lung Cancer Res, 4, 191 Uramoto, 2014, Recurrence after surgery in patients with NSCLC, Transl Lung Cancer Res, 3, 242 Buhl, 2018, Molecular prediction of adjuvant cisplatin efficacy in Non-Small Cell Lung Cancer (NSCLC)—Validation in two independent cohorts, PLoS ONE, 13, 10.1371/journal.pone.0194609 Wallerek, 2015, Biomarkers for efficacy of adjuvant chemotherapy following complete resection in NSCLC stages I–IIIA, Eur Respiratory Rev, 24, 340, 10.1183/16000617.00005814 Olaussen, 2006, DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy, N Engl J Med, 355, 983, 10.1056/NEJMoa060570 Pierceall, 2012, Cisplatin benefit is predicted by immunohistochemical analysis of DNA repair proteins in squamous cell carcinoma but not adenocarcinoma: theranostic modeling by NSCLC constituent histological subclasses, Ann Oncol, 23, 2245, 10.1093/annonc/mdr624 Sorensen, 2015, Intravenous or oral administration of vinorelbine in adjuvant chemotherapy with cisplatin and vinorelbine for resected NSCLC, Lung Cancer, 88, 167, 10.1016/j.lungcan.2015.02.010 Hubbard, 2012, Five-year survival does not equal cure in non-small cell lung cancer: a Surveillance, Epidemiology, and End Results-based analysis of variables affecting 10- to 18-year survival, Thorac Cardiovasc Surg, 1307, 10.1016/j.jtcvs.2012.01.078 Norton, 1976, Predicting the course of Gompertzian growth, Nature, 264, 542, 10.1038/264542a0